2016
DOI: 10.1016/j.humimm.2016.01.008
|View full text |Cite
|
Sign up to set email alerts
|

Nonclassical human leukocyte antigen (HLA-G, HLA-E, and HLA-F) in coronary artery disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
7
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 15 publications
(7 citation statements)
references
References 32 publications
0
7
0
Order By: Relevance
“…Furthermore, this hypothesis is corroborated by an investigation at the level of the coronary artery disease which concluded that non-classical HLA class I molecules are capable of inducing an immune tolerant microenvironment. 34…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Furthermore, this hypothesis is corroborated by an investigation at the level of the coronary artery disease which concluded that non-classical HLA class I molecules are capable of inducing an immune tolerant microenvironment. 34…”
Section: Discussionmentioning
confidence: 99%
“…However, the association of positive staining for HLA-G in association with SARS-CoV-2 warrants further investigations in order to understand the possible role of the former as pro-thrombotic inductor. 20,34,40…”
Section: Discussionmentioning
confidence: 99%
“…HLA-DRA [148], SERPINA1 [149], ABHD12 [150], IMPA2 [151], ARSA (arylsulfatase A) [152], LRFN5 [153], PLXNA4 [154], CHL1 [155], ITPKB (inositol-trisphosphate 3-kinase B) [156], PTN (pleiotrophin) [157], LAMA2 [158], CDH6 [159] and A2M [160] have been shown to have an important role in neurological disorders, but these genes might be associated with progression of T2DM. HLA-F [161], HLA-H [162], FGA (fibrinogen alpha chain) [163], HSPA1B [164], MRC1 [165], DAB2IP [166], KCNJ8 [167], KLKB1 [168], CXCL2 [169], SERPINE2 [170], ADH1C [171], AMBP (alpha-1-microglobulin/bikunin precursor) [172], NR4A2 [173], TYMP (thymidine phosphorylase) [174], TFRC (transferrin receptor) [175], PLAU (plasminogen activator, urokinase) [176], COL6A2 [177], COL15A1 [178], ABI3BP [179], NEXN (nexilin F-actin binding protein) [180], S1PR1 [181], THY1 [182], COL4A1 [183], COL5A2 [184], ADAMTS2 [185], ECM1 [186] and LTBP2 [187] have been found to be differentially expressed in cardiovascular diseases, but these genes might be linked with progression of T2DM. CCL20 [188], CRH (corticotropin releasing hormone) [189], SPP1 [190], LDLR (low density lipoprotein receptor) [191], RORA (RAR related orphan receptor A) [192], LYZ (lysozyme) [193], PTPRN2 [194], DAPK2 [195], OIP5 [196], PON3 [197], NR4A3 [198], VCAN (versican) [199], CNTNAP2 [200], IL1RAP [201], GLI2 [202], CDH13 [203], AEBP1 [204], BGN (biglycan) [205], LOX (lysyl oxidase) [206], IL1RL1 [207] and LUM (lumican) [208] were found to be involved in advancement of obesity, but these genes might be key for development of T2DM.…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, in the literature, it is already known that HLA-G expression is modified by several genetic polymorphisms (SNPs)and some reports showed the association between SNPs and CHD risk although there is no evidence at transcriptomic level [ 30 32 ]. SNPs in distinct regions can play a relevant role both at transcriptional and protein levels, influencing binding of specific microRNAs and relative gene expression.…”
Section: Discussionmentioning
confidence: 99%